COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN CANADA

被引：0
|
作者：
Amadi, A. [1 ]
Toor, K. [2 ]
Keeney, E. [3 ]
Thom, H. [4 ]
Singh, P. [5 ]
Kim, I [6 ]
Mameri, E. [7 ]
机构：
[1] Bristol Myers Squibb, Uxbridge, BC, Canada
[2] Precis Xtract, Vancouver, BC, Canada
[3] Univ Bristol, Bristol, Avon, England
[4] Univ Bristol, GLS, Bristol, Avon, England
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Bristol Myers Squibb, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA39
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial
    Huang, Jiaxing
    Liao, Weiting
    Zhou, Jing
    Zhang, Pengfei
    Wen, Feng
    Wang, Xinyuan
    Zhang, Mengxi
    Zhou, Kexun
    Wu, Qiuji
    Li, Qiu
    [J]. CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 4065 - 4072
  • [32] Adjuvant chemoradiotherapy in patients (pts) with resectable gastric (GC) or gastroesophageal junction cancer (GEJC): A monoinstitutional experience
    Soini, Barbara
    Pani, Giuseppe
    Caffo, Orazio
    Frisinghelli, Michela
    Veccia, Antonello
    Brugnara, Sonia
    Caldara, Alessia
    DiPasquale, MariaChiara
    Ferro, Antonella
    Mussari, Salvatore
    Murgia, Viviana
    Russo, Lucianna
    Valduga, Francesco
    Tumulo, Salvatore
    Galligioni, Enzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A multicountry chart review of treatment patterns and outcomes for patients with resected esophageal or gastroesophageal junction cancer.
    Singh, Prianka
    Gricar, Joseph
    Mackie, deMauri S.
    Xiao Hong
    DeCongelio, Marc
    Jaffe, Dena H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [34] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Peng-Fei Zhang
    Xuan-Qiong Shi
    Qiu Li
    [J]. Cost Effectiveness and Resource Allocation, 21
  • [35] Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Shi, Xuan-Qiong
    Li, Qiu
    [J]. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [36] Cost-effectiveness of adjuvant chemotherapy in resected non-small cell cancer
    Messori, Andrea
    Caccese, Erminia
    Cecchi, Michele
    Orsi, Cecilia
    Tendi, Enrico
    [J]. PHARMACY WORLD & SCIENCE, 2007, 29 (05): : 486 - 486
  • [37] Nivolumab a New Standard of Care in Adjuvant Settings in Esophageal and Gastroesophageal Junctional Cancer Patients
    Rajappa, Senthil J.
    Nusrath, Syed
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (05) : 468 - 469
  • [38] Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
    Shu, Yamin
    Ding, Yufeng
    Zhang, Qilin
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Adjuvant FOLFIRINOX in Patients with Resected Pancreatic Ductal Adenocarcinoma: A Cost-effectiveness Analysis
    Hersh, A. R.
    Buuck, T.
    Wagner, J.
    Kardosh, A.
    Caughey, A.
    Mayo, S. C.
    Billingsley, K. G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S45 - S45
  • [40] Cost-effectiveness analysis of bicalutamide (Casodex™) for adjuvant treatment of early prostate cancer
    Moeremans, K
    Caekelbergh, K
    Annemans, L
    [J]. VALUE IN HEALTH, 2004, 7 (04) : 472 - 481
12345